Back to top
more

Enzo Biochem (ENZ)

(Delayed Data from NYSE)

$1.05 USD

1.05
114,913

-0.02 (-1.87%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ENZ

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Enzo Biochem, Inc falls in the month of July.

All items in Millions except Per Share data.

7/31/2023 7/31/2022 7/31/2021 7/31/2020 7/31/2019
Assets          
Cash & Equivalents 82 22 44 48 60
Receivables 5 12 10 9 11
Notes Receivable 0 0 0 0 0
Inventories 8 15 13 8 8
Other Current Assets 3 6 4 4 3
Total Current Assets 98 54 71 69 81
Net Property & Equipment 13 17 17 14 14
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 1 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 7 8 8 8
Deposits & Other Assets 6 2 2 1 2
Total Assets 122 96 114 113 107
Liabilities & Shareholders Equity 7/31/2023 7/31/2022 7/31/2021 7/31/2020 7/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 4 9 8 9 7
Current Portion Long-Term Debt 0 0 0 7 0
Current Portion Capital Leases 3 0 0 0 0
Accrued Expenses 12 12 14 13 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 21 0 0 0 0
Total Current Liabilities 40 25 26 33 16
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 4 4 4 4
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 43 41 45 54 21
Shareholders Equity 7/31/2023 7/31/2022 7/31/2021 7/31/2020 7/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 0 0 0 0
Capital Surplus 344 339 337 334 333
Retained Earnings -268 -289 -270 -278 -250
Other Equity 2 3 1 2 3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 78 54 69 58 86
Total Liabilities & Shareholder's Equity 122 96 114 113 107
Total Common Equity 78 54 69 58 86
Shares Outstanding 49.60 48.70 48.40 47.80 47.50
Book Value Per Share 1.58 1.12 1.42 1.22 1.81

Fiscal Year End for Enzo Biochem, Inc falls in the month of July.

All items in Millions except Per Share data.

1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023
Assets          
Cash & Equivalents 60 69 82 3 5
Receivables 5 4 5 10 11
Notes Receivable 0 0 0 0 0
Inventories 8 8 8 15 16
Other Current Assets 8 7 3 4 5
Total Current Assets 81 88 98 32 36
Net Property & Equipment 13 13 13 18 17
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 1 1 1 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 7 7
Deposits & Other Assets 1 1 6 2 2
Total Assets 99 106 122 72 76
Liabilities & Shareholders Equity 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 1 2 4 14 13
Current Portion Long-Term Debt 0 0 0 7 4
Current Portion Capital Leases 3 3 3 0 0
Accrued Expenses 8 10 12 17 12
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 13 21 0 0
Total Current Liabilities 25 29 40 42 32
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 28 32 43 53 44
Shareholders Equity 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 346 346 344 342 340
Retained Earnings -278 -275 -268 -326 -311
Other Equity 2 3 2 2 3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 71 74 78 19 33
Total Liabilities & Shareholder's Equity 99 106 122 72 76
Total Common Equity 71 74 78 19 33
Shares Outstanding 50.40 50.40 49.60 49.60 48.70
Book Value Per Share 1.40 1.47 1.58 0.38 0.67